SCHEMBL13884986

C/C=C/C(O)C(CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@]3(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)C([C@H](O)[C@H](O)CO)O3)[C@H]2O)[C@H](O)[C@H]1O)NC(=O)C(C)CCCCCCCCCCCCCCC

nearest known ligand 0.59

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	SIGLEC7	Q9Y286	6/20	0.59

▸	MAG	P20916	8/20	0.51

▸	SELL	P14151	2/20	0.49

▸	SELP	P16109	2/20	0.49

▸	SELE	P16581	2/20	0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL16491226	0.92	SIGLEC7 (0.61)	SIGLEC7MAGSELLSELPSELE
SCHEMBL19427378	0.90	SIGLEC7 (0.63)	SIGLEC7MAGSELLSELPSELE
SCHEMBL12313945	0.88	SIGLEC7 (0.62)	SIGLEC7MAGSELLSELPSELE
SCHEMBL27393848	0.87	SIGLEC7 (0.55)	SIGLEC7MAGSELLSELPSELE
SCHEMBL17611789	0.87	SIGLEC7 (0.62)	SIGLEC7MAGSELLSELPSELE
SCHEMBL29693389	0.87	SIGLEC7 (0.64)	SIGLEC7MAGSELLSELPSELE
SCHEMBL29361332	0.87	SIGLEC7 (0.64)	SIGLEC7MAGSELLSELPSELE
SCHEMBL21552197	0.87	SIGLEC7 (0.64)	SIGLEC7MAGSELLSELPSELE
SCHEMBL16449748	0.86	SIGLEC7 (0.59)	SIGLEC7MAGSELLSELP
SCHEMBL1487635	0.86	SIGLEC7 (0.59)	SIGLEC7MAGSELLSELPSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20170281593-A1	Methods of Treating Fatty Liver Disease	GENZYME CORPORATION	2017-10-05	—	—	US	disclosed
US-8716327-B2	Methods of treating fatty liver disease	GENZYME CORPORATION (US)	2014-05-06	—	—	US	disclosed
US-20090105125-A1	Methods of Treating Fatty Liver Disease	GENZYME CORPORATION	2009-04-23	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20170281593-A1	Methods of Treating Fatty Liver Disease	LIPC, GYS2, PNLIP	SIGLEC7 1500/4885MAG 1387/4885SELL 2670/4885
US-20090105125-A1	Methods of Treating Fatty Liver Disease	LIPC, GYS2, PNLIP	SIGLEC7 1500/4885MAG 1387/4885SELL 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.